Distribution of clinicopathological parameters
| MMRs | MMRi | p53+ | Total | p-value | |
|---|---|---|---|---|---|
| Number of patients | 480 | 170 | 128 | 778 | |
| Age at diagnosis | < 0.001 | ||||
| Mean (SD) | 61.4 (11.1) | 63.8 (10.5) | 68.8 (9.4) | 63.1 (11.0) | |
| Range | 25.0 – 87.0 | 29.0 – 88.0 | 46.0 – 89.0 | 25.0 – 89.0 | |
| BMI | 0.136 | ||||
| Mean (SD) | 30.4 (8.9) | 30.9 (8.1) | 29.0 (6.7) | 30.3 (8.4) | |
| Range | 16.8 – 121.0 | 17.4 – 64.1 | 17.2 – 51.9 | 16.8 – 121.0 | |
| FIGO_stage | < 0.001 | ||||
| IA | 298 (62.1%) | 86 (50.6%) | 49 (38.3%) | 433 (55.7%) | |
| IB | 113 (23.5%) | 44 (25.9%) | 37 (28.9%) | 194 (24.9%) | |
| II | 28 (5.8%) | 16 (9.4%) | 19 (14.8%) | 63 (8.1%) | |
| IIIA | 5 (1.0%) | 3 (1.8%) | 3 (2.3%) | 11 (1.4%) | |
| IIIB | 5 (1.0%) | 0 (0.0%) | 3 (2.3%) | 8 (1.0%) | |
| IIIC1 | 25 (5.2%) | 14 (8.2%) | 12 (9.4%) | 51 (6.6%) | |
| IIIC2 | 1 (0.2%) | 2 (1.2%) | 0 (0.0%) | 3 (0.4%) | |
| IVA | 0 (0.0%) | 3 (1.8%) | 1 (0.8%) | 4 (0.5%) | |
| IVB | 5 (1.0%) | 2 (1.2%) | 4 (3.1%) | 11 (1.4%) | |
| Early stage (I-II) | 0.005 | ||||
| no | 41 (8.5%) | 24 (14.1%) | 23 (18.0%) | 88 (11.3%) | |
| yes | 439 (91.5%) | 146 (85.9%) | 105 (82.0%) | 690 (88.7%) | |
| Tumor grade | < 0.001 | ||||
| G1-2 | 420 (87.5%) | 131 (77.1%) | 6 (4.7%) | 557 (71.6%) | |
| G3 | 60 (12.5%) | 39 (22.9%) | 122 (95.3%) | 221 (28.4%) | |
| Histotype | < 0.001 | ||||
| Type I | 450 (93.8%) | 161 (94.7%) | 16 (12.5%) | 627 (80.6%) | |
| Type II | 30 (6.2%) | 9 (5.3%) | 112 (87.5%) | 151 (19.4%) | |
| LVSI | < 0.001 | ||||
| Negative | 401 (83.7%) | 128 (76.2%) | 76 (61.3%) | 605 (78.5%) | |
| Positive | 78 (16.3%) | 40 (23.8%) | 48 (38.7%) | 166 (21.5%) | |
| Myometrial invasion | 0.003 | ||||
| ≤ 50 | 324 (67.6%) | 101 (59.8%) | 67 (52.3%) | 492 (63.4%) | |
| > 50 | 155 (32.4%) | 68 (40.2%) | 61 (47.7%) | 284 (36.6%) | |
| Tumor dimension (class) | 0.584 | ||||
| ≤ 20 mm | 117 (24.4%) | 37 (21.8%) | 27 (21.1%) | 181 (23.3%) | |
| > 20 mm | 360 (75.0%) | 133 (78.2%) | 101 (78.9%) | 594 (76.3%) | |
| Tumor dimension | < 0.001 | ||||
| Mean (SD) | 33.1 (18.1) | 35.200 (16.314) | 40.3 (25.9) | 34.8 (19.4) | |
| Range | 1.0 – 140.0 | 1.0 – 95.0 | 1.0 – 150.0 | 1.0 – 150.0 | |
| Pathological lymph node status | 0.057 | ||||
| Negative | 468 (97.5%) | 159 (93.5%) | 123 (96.1%) | 750 (96.4%) | |
| Positive | 12 (2.5%) | 11 (6.5%) | 5 (3.9%) | 28 (3.6%) | |
| Post-surgical treatment | 0.082 | ||||
| None | 212 (45.0%) | 90 (54.9%) | 55 (45.1%) | 357 (47.2%) | |
| Any | 259 (55.0%) | 74 (45.1%) | 67 (54.9%) | 400 (52.8%) | |
| Adjuvant CHT | 0.093 | ||||
| No | 282 (59.9%) | 113 (68.1%) | 69 (56.6%) | 464 (61.1%) | |
| Yes | 189 (40.1%) | 53 (31.9%) | 53 (43.4%) | 295 (38.9%) | |
| Adjuvant RT | 0.540 | ||||
| No | 229 (47.7%) | 89 (52.4%) | 65 (50.8%) | 383 (49.2%) | |
| Yes | 251 (52.3%) | 81 (47.6%) | 63 (49.2%) | 395 (50.8%) | |
| Risk class 2020 | < 0.001 | ||||
| Low | 260 (54.2%) | 72 (42.4%) | 1 (0.8%) | 333 (42.8%) | |
| Intermediate | 79 (16.5%) | 25 (14.7%) | 11 (8.6%) | 115 (14.8%) | |
| High/intermediate | 80 (16.7%) | 44 (25.9%) | 8 (6.2%) | 132 (17.0%) | |
| High | 56 (11.7%) | 27 (15.9%) | 104 (81.2%) | 187 (24.0%) | |
| Advanced/Metastatic | 5 (1.0%) | 2 (1.2%) | 4 (3.1%) | 11 (1.4%) | |